keyword
https://read.qxmd.com/read/34779087/a-randomized-clinical-trial-of-the-efficacy-and-safety-of-sitagliptin-as-initial-oral-therapy-in-youth-with-type-2-diabetes
#21
RANDOMIZED CONTROLLED TRIAL
R Ravi Shankar, Philip Zeitler, Asma Deeb, Muhammad Yazid Jalaludin, Raymundo Garcia, Ron S Newfield, Yulia Samoilova, Carmen A Rosario, Naim Shehadeh, Chandan K Saha, Yilong Zhang, Martina Zilli, Lynn W Scherer, Raymond L H Lam, Gregory T Golm, Samuel S Engel, Keith D Kaufman
OBJECTIVE: To assess the efficacy and safety of DPP-4 inhibition with sitagliptin in youth with type 2 diabetes (T2D). STUDY DESIGN: This was a 54-week, double-blind, randomized, controlled clinical trial evaluating the safety and efficacy of DPP-4 inhibition with sitagliptin 100 mg once daily as initial oral therapy in youth with T2D. The 190 participants, aged 10-17 years, had HbA1c 6.5%-10% (7.0%-10% if on insulin). All were negative for pancreatic autoantibodies and overweight/obese at screening or diagnosis...
March 2022: Pediatric Diabetes
https://read.qxmd.com/read/34678732/a-novel-gpr119-agonist-da-1241-preserves-pancreatic-function-via-the-suppression-of-er-stress-and-increased-pdx1-expression
#22
JOURNAL ARTICLE
Mi-Kyung Kim, Ye Hwang Cheong, Seung Ho Lee, Tae Hyoung Kim, Il Hoon Jung, Yuna Chae, Jeong-Ha Lee, Eun Kyoung Yang, Hansu Park, Jae-Sung Yang, Ki Whan Hong
DA-1241 is a novel small molecule G protein-coupled receptor 119 (GPR119) agonist in early clinical development for type 2 diabetic patients. This study aimed to elucidate the pharmacological characteristics of DA-1241 for its hypoglycemic action. DA-1241 potently and selectively activated GPR119 with enhanced maximum efficacy. DA-1241 increased intracellular cAMP in HIT-T15 insulinoma cells (EC50 , 14.7 nM) and increased insulin secretion (EC50 , 22.3 nM) in association with enhanced human insulin promoter activity...
December 2021: Biomedicine & Pharmacotherapy
https://read.qxmd.com/read/34652439/corrigendum-to-effect-of-sitagliptin-on-islet-function-in-pancreatic-insufficient-cystic-fibrosis-with-abnormal-glucose-tolerance
#23
(no author information available yet)
No abstract text is available yet for this article.
October 15, 2021: Journal of Clinical Endocrinology and Metabolism
https://read.qxmd.com/read/34635643/sitagliptin-activates-the-p62-keap1-nrf2-signalling-pathway-to-alleviate-oxidative-stress-and-excessive-autophagy-in-severe-acute-pancreatitis-related-acute-lung-injury
#24
JOURNAL ARTICLE
Lingming Kong, Jie Deng, Xiang Zhou, Binbin Cai, Baofu Zhang, Xiaohu Chen, Zongjing Chen, Weiming Wang
Acute lung injury (ALI) is a complication of severe acute pancreatitis (SAP). Sitagliptin (SIT) is a DPP4 inhibitor that exerts anti-inflammatory and antioxidant effects; however, its mechanism of action in SAP-ALI remains unclear. In this study, we investigated the effects of SIT on SAP-ALI and the specific pathways involved in SAP-induced lung inflammation, including oxidative stress, autophagy, and p62-Kelch-like ECH-associated protein 1 (Keap1)-NF-E2-related factor 2 (Nrf2) signalling pathways. Nrf2 knockout (Nrf2-/- ) and wild-type (WT) mice were pre-treated with SIT (100 mg/kg), followed by caerulein and lipopolysaccharide (LPS) administration to induce pancreatic and lung injury...
October 11, 2021: Cell Death & Disease
https://read.qxmd.com/read/34480721/the-effect-of-verapamil-on-txnip-gene-expression-glp1r-mrna-fbs-hba1c-and-lipid-profile-in-t2dm-patients-receiving-metformin-and-sitagliptin
#25
JOURNAL ARTICLE
Alireza Malayeri, Mehrnoosh Zakerkish, Farrokh Ramesh, Hamid Galehdari, Ali Asghar Hemmati, Kambiz A Angali
INTRODUCTION: Type 2 diabetes mellitus (T2DM) is the most common type of diabetes. A decrease in the number of pancreatic beta cells is a pathological sign of diabetes, and to date there is no drug treatment that targets damage to these cells. Pancreatic beta cells have a weak antioxidant system and are highly sensitive to oxidative stress reactions that occur within cells. Thioredoxin interacting protein (TXNIP) inhibits thioredoxin, which is part of the intracellular antioxidant system, thereby accelerating oxidative stress and apoptosis of pancreatic beta cells...
September 4, 2021: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://read.qxmd.com/read/34406395/effect-of-sitagliptin-on-islet-function-in-pancreatic-insufficient-cystic-fibrosis-with-abnormal-glucose-tolerance
#26
RANDOMIZED CONTROLLED TRIAL
Andrea Kelly, Saba Sheikh, Darko Stefanovski, Amy J Peleckis, Sarah C Nyirjesy, Jack N Eiel, Aniket Sidhaye, Russell Localio, Robert Gallop, Diva D De Leon, Denis Hadjiliadis, Ronald C Rubenstein, Michael R Rickels
PURPOSE: Impaired incretin secretion may contribute to the defective insulin secretion and abnormal glucose tolerance (AGT) that associate with worse clinical outcomes in pancreatic insufficient cystic fibrosis (PI-CF). The study objective was to test the hypothesis that dipeptidyl peptidase-4 (DPP-4) inhibitor-induced increases in intact incretin hormone [glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)] concentrations augment insulin secretion and glucagon suppression and lower postprandial glycemia in PI-CF with AGT...
August 18, 2021: Journal of Clinical Endocrinology and Metabolism
https://read.qxmd.com/read/34378827/neurotensin-secretion-after-roux-en-y-gastric-bypass-sleeve-gastrectomy-and-truncal-vagotomy-with-pyloroplasty
#27
JOURNAL ARTICLE
Maria S Svane, Caroline C Øhrstrøm, Astrid Plamboeck, Nils B Jørgensen, Kirstine N Bojsen-Møller, Carsten Dirksen, Christoffer Martinussen, Tina Vilsbøll, Bolette Hartmann, Carolyn F Deacon, Viggo B Kristiansen, Filip K Knop, Lars B Svendsen, Sten Madsbad, Jens J Holst, Simon Veedfald
OBJECTIVE: Neurotensin (NT) is released from enteroendocrine cells and lowers food intake in rodents. We evaluated postprandial NT secretion in humans after surgeries associated with accelerated small intestinal nutrient delivery, and after Roux-en-Y gastric bypass (RYGB) when glucagon-like peptide-1 (GLP-1) signalling and dipeptidyl peptidase 4 (DPP-4) were inhibited, and during pharmacological treatments influencing entero-pancreatic functions. METHODS: We measured NT concentrations in plasma from meal studies: (I) after truncal vagotomy with pyloroplasty (TVP), cardia resection +TVP (CTVP), and matched controls (n = 10); (II) after RYGB, sleeve gastrectomy (SG), and in matched controls (n = 12); (III) after RYGB (n = 11) with antagonism of GLP-1 signalling using exendin(9-39) and DPP-4 inhibition using sitagliptin; (IV) after RYGB (n = 11) during a run-in period and subsequent treatment with, sitagliptin, liraglutide (GLP-1 receptor agonist), verapamil (calcium antagonist), acarbose (alpha glucosidase inhibitor), and pasireotide (somatostatin analogue), respectively...
January 2022: Neurogastroenterology and Motility: the Official Journal of the European Gastrointestinal Motility Society
https://read.qxmd.com/read/34360322/in-situ-neutral-system-synthesis-spectroscopic-and-biological-interpretations-of-magnesium-ii-calcium-ii-chromium-iii-zinc-ii-copper-ii-and-selenium-iv-sitagliptin-complexes
#28
JOURNAL ARTICLE
Samy M El-Megharbel, Moamen S Refat, Fawziah A Al-Salmi, Reham Z Hamza
Magnesium(II), calcium(II), chromium(III), zinc(II), copper(II), and selenium(IV) sitagliptin (STG) complexes-with the general formulas [Mg(STG)2 (Cl)2 ]·6H2 O, [Ca(STG)2 (Cl)2 ], [Cr(STG)2 (Cl)2 ]Cl.6H2 O, [Zn(STG)2 (Cl)2 ], [Cu(STG)2 (Cl)2 ]·2H2 O, and [Se(STG)2 (Cl)2 ]Cl2 , respectively-were designed and synthesized by the chemical reactions between metal(II, III, and IV) chloride salts with an STG ligand in situ methanol solvent in a 1:2 stoichiometric ratio (metal:ligand). Tentative structures of the complexes were proposed based on elemental analysis, molar conductance, magnetic moments, thermogravimetric analysis, and spectral (infrared, electronic, and 1 H NMR) data...
July 29, 2021: International Journal of Environmental Research and Public Health
https://read.qxmd.com/read/34022051/randomized-controlled-trial-of-sitagliptin-and-islet-function-in-cystic-fibrosis-with-abnormal-glucose-tolerance
#29
JOURNAL ARTICLE
Andrea Kelly, Saba Sheikh, Darko Stefanovski, Amy J Peleckis C R N P, Sarah C Nyirjesy, Jack N Eiel, Aniket Sidhaye, Russell Localio, Robert Gallop, Diva D De Leon, Denis Hadjiliadis, Ronald C Rubenstein, Michael R Rickels
PURPOSE: Impaired incretin secretion may contribute to the defective insulin secretion and abnormal glucose tolerance (AGT) that associate with worse clinical outcomes in pancreatic insufficient cystic fibrosis (PI-CF). The study objective was to test the hypothesis that dipeptidyl peptidase-4 (DPP-4) inhibitor-induced increases in intact incretin hormone (glucagon-like peptide-1 [GLP-1] and glucose-dependent insulinotropic polypeptide [GIP]) concentrations augment insulin secretion and glucagon suppression and lower post-prandial glycemia in PI-CF with AGT...
May 22, 2021: Journal of Clinical Endocrinology and Metabolism
https://read.qxmd.com/read/33674210/chronic-incretin-based-therapy-in-cystic-fibrosis-related-diabetes-a-tale-of-3-patients-treated-with-sitagliptin-for-over-5-years
#30
Samuel T Olatunbosun
Cystic fibrosis-related diabetes (CFRD) affects 40-50% of adult patients with cystic fibrosis. Insulin therapy is recommended but there are therapeutic challenges, particularly risk of hypoglycemia and aversion of some patients to injectables. An oral incretin-based therapy using a DPP-4i (dipeptidyl peptidase-4 inhibitor), may be a reasonable option, especially in the early stage of the disease. The effect of chronic incretin-based therapy on CFRD is unknown. Here is a report of 3 cases of CFRD patients treated with sitagliptin and the response to therapy over a period of 5-10 years...
November 2021: Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society
https://read.qxmd.com/read/33588009/alleviation-of-diabetes-mellitus-through-the-restoration-of-%C3%AE-cell-function-and-lipid-metabolism-by-aloe-vera-l-burm-f-extract-in-obesogenic-wnin-gr-ob-rats
#31
JOURNAL ARTICLE
Neha Deora, M M Sunitha, M Satyavani, N Harishankar, Mookambeswaran A Vijayalakshmi, Krishnan Venkataraman, Vijayalakshmi Venkateshan
ETHNOPHARMACOLOGICAL RELEVANCE: Aloe vera (L.) Burm. f. extract has been medicinally used for over 5000 years in different cultures for its curative and therapeutic properties ranging from dermatitis to diabetes. It has been demonstrated to alleviate diabetes through its protective effects on pancreatic islets and by improving insulin secretion. AIM OF THE STUDY: To investigate the simultaneous effect of ethanolic A. vera gel extract on diabetes and obesogenic milieu in Streptozotocin-induced WNIN/GR-Ob mutant obese rats...
February 12, 2021: Journal of Ethnopharmacology
https://read.qxmd.com/read/33574715/successful-control-of-hypoglycemia-with-pasireotide-lar-in-a-patient-with-inappropriate-insulin-secretion
#32
Alexia Rouland, Benjamin Bouillet, Pauline Legris, Isabelle Simoneau, Jean-Michel Petit, Bruno Vergès
Introduction: Inappropriate insulin secretion could be due to several diseases. Nesidioblastosis is characterized by diffuse hyperplasia of pancreatic beta cells, causing organic hypoglycemia. No pancreatic lesions are found on the imaging of patients with this condition. Diazoxide is used as a first-line treatment but can be poorly tolerated because of its side effects, and therapeutic failure is possible. Somatostatin analogues have limited efficacy because of their poor affinity to somatostatin (SST) receptors...
2021: Clinical Pharmacology: Advances and Applications
https://read.qxmd.com/read/33512261/combined-treatment-with-a-gastric-inhibitory-polypeptide-receptor-antagonist-and-a-peptidyl-peptidase-4-inhibitor-improves-metabolic-abnormalities-in-diabetic-mice
#33
JOURNAL ARTICLE
Fei Yang, Shan Dang, Hongjun Lv, Bingyin Shi
OBJECTIVES: Dipeptidyl peptidase-4 inhibition and gastric inhibitory polypeptide (GIP) receptor antagonism have therapeutic effects in type 2 diabetes mellitus. We assessed the effects of sitagliptin and Pro3 (GIP) in a mouse model of diabetes. METHODS: Diabetes was induced in C57BL/6J mice by a high-fat diet and intraperitoneal injection of streptozocin. Blood glucose was assessed weekly. Six weeks later, serum triglycerides, total cholesterol and glucose tolerance were assessed and pancreatic and adipose tissues were collected...
January 2021: Journal of International Medical Research
https://read.qxmd.com/read/33453239/chronic-treatment-with-anti-gipr-mab-alone-and-combined-with-dpp-4-inhibitor-correct-obesity-dyslipidemia-and-nephropathy-in-rodent-animals
#34
JOURNAL ARTICLE
Jiawei Chen, Songsong Zheng, Yongbin Hu, Xin Mou, Huiyang Wang
OBJECTIVE: Glucose-dependent insulinotropic polypeptide receptor (GIPR) has been identified as a contributor to obesity, and GIPR knockout mice are protected against diet-induced obesity (DIO). Therefore, we developed the anti-GIPR antagonistic monoclonal antibody (mAb) alone and in combination with DPP-4 inhibitor as potential therapeutic strategy for treating obesity and dyslipidemia based on this genetic evidence. METHODS: Fully neutralized GIPR activity of GIPR-monoclonal antibody (mAb) was assessed by regulating the in vitro production of cAMP in the mouse GIPR stably expressing cells...
January 13, 2021: Life Sciences
https://read.qxmd.com/read/33434602/efficacy-and-safety-of-the-glucagon-like-peptide-1-receptor-agonist-oral-semaglutide-in-patients-with-type-2-diabetes-mellitus-a-systematic-review-and-meta-analysis
#35
JOURNAL ARTICLE
Jingxin Li, Ke He, Jun Ge, Caixia Li, Zeng Jing
OBJECTIVES: To evaluate the efficacy and safety of the glucagon-like peptide-1 (GLP-1) receptor agonist (RA) oral semaglutide in the treatment of type 2 diabetes mellitus (T2DM) patients. METHODS: Randomized controlled trials comparing oral semaglutide with placebo or other antihyperglycemic agents in T2DM patients were identified by searching PubMed, Embase, Cochrane Library and ClinicalTrials.gov. Risk ratios and mean differences with 95% confidence intervals were used to synthesize the results...
February 2021: Diabetes Research and Clinical Practice
https://read.qxmd.com/read/33279496/the-methionine-aminopeptidase-2-inhibitor-tnp-470-enhances-the-antidiabetic-properties-of-sitagliptin-in-mice-by-upregulating-xenin
#36
JOURNAL ARTICLE
Sarah L Craig, Victor A Gault, Peter R Flatt, Nigel Irwin
The therapeutic mechanism of action of methionine aminopeptidase 2 (MetAP2) inhibitors for obesity-diabetes has not yet been fully defined. Xenin, a K-cell derived peptide hormone, possesses an N-terminal Met amino acid residue. Thus, elevated xenin levels could represent a potential pharmacological mechanism of MetAP2 inhibitors, since long-acting xenin analogues have been shown to improve obesity-diabetes. The present study has assessed the ability of the MetAP2 inhibitor, TNP-470, to augment the antidiabetic utility of the incretin-enhancer drug, sitagliptin, in high fat fed (HFF) mice...
December 3, 2020: Biochemical Pharmacology
https://read.qxmd.com/read/33239410/higher-dose-sitagliptin-and-the-risk-of-congestive-heart-failure-in-older-adults-with-ckd
#37
JOURNAL ARTICLE
Flory T Muanda, Matthew A Weir, Lavanya Bathini, Kristin K Clemens, Vlado Perkovic, Manish M Sood, Eric McArthur, Jessica M Sontrop, Richard B Kim, Amit X Garg
BACKGROUND AND OBJECTIVES: Sitagliptin, a dipeptidyl peptidase-4 inhibitor, is commonly prescribed to patients with type 2 diabetes. As this drug is primarily eliminated by the kidney, a reduced dose is recommended for patients with CKD. Some evidence suggests that sitagliptin is associated with a higher risk of congestive heart failure, particularly at higher doses. We compare the 1-year risk of death or hospitalization with congestive heart failure in patients with CKD newly prescribed sitagliptin at >50 versus ≤50 mg/d...
November 25, 2020: Clinical Journal of the American Society of Nephrology: CJASN
https://read.qxmd.com/read/33224612/evaluation-of-the-use-of-sitagliptin-for-insulin-resistance-in-burn-patients
#38
JOURNAL ARTICLE
Kaitlin A Pruskowski, Beth A Shields, Craig R Ainsworth, Leopoldo C Cancio
BACKGROUND: Following severe burn injury, patients undergo profound metabolic changes, including insulin resistance and hyperglycemia. Hyperglycemia has been linked to impaired wound healing, increased risk of skin graft loss, increased muscle catabolism, increased infections, and mortality. Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that improves glycemic control by slowing the inactivation of incretin hormones, increasing insulin synthesis and release from pancreatic beta cells and lowering glucagon secretion from pancreatic alpha cells...
2020: International Journal of Burns and Trauma
https://read.qxmd.com/read/33191818/link-between-serum-uric-acid-and-pancreatic-beta-cell-function-in-drug-na%C3%A3-ve-subjects-with-type-2-diabetes-treated-with-sitagliptin
#39
JOURNAL ARTICLE
Eiji Kutoh, Askuka Wada, Alexandra N Kuto, Jyunka Hayashi, Rumi Kurihara
Aim : The objective of this study is to investigate the changes of UA with sitagliptin in relation to its glycemic/non-glycemic efficacies. Methods : Drug naïve subjects with T2DM (n = 62) were administered 25-50 mg/day sitagliptin monotherapy for 3 months. The subjects were divided into two subgroups according to the changes in (Δ) UA (above the median [group A, n = 31]: ΔUA = 23.3%, p < 0.00001, and below the median [group B, n = 31]: ΔUA = -0.9%, n.s.). Changes in glycemic/non-glycemic parameters were compared between these two groups, which acted as a control for each other...
November 30, 2020: Hospital Practice (Minneapolis)
https://read.qxmd.com/read/33163625/linagliptin-induced-pancreatitis
#40
Jorge Esteban Mosquera, Nancy Torres, Jorge Restrepo, Carlos Ruz-Pau, Sowmya Suryanarayanan
Objective: To report a case of linagliptin-induced acute pancreatitis and remind clinicians about risks with incretin-based drugs. Patients at risk for pancreatitis should be switched to another type of hypoglycemic treatment. Methods: We present the case of a 74-year-old Latina who presented to the emergency department with sudden onset of epigastric pain radiating to her back. Medical history, physical exam, laboratory tests, and medical images were compatible with acute pancreatitis...
January 2020: AACE Clinical Case Reports
keyword
keyword
74519
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.